Ulf Wiinberg

Ulf Wiinberg is the current President & Chief Executive Officer at X-Vax Technology. Ulf has also served as the CEO of Lundbeck from June 2008 to December 2014, and as the President Europe/Middle East/Africa at Wyeth from June 2005 to May 2008.

Wiinberg has been credited with rejuvenating the pipeline and expanding geographies at Lundbeck, as well as increasing revenue by 22% despite losing 7 billion DKK to generics. Ulf has also been credited with growing sales and Ebit at Wyeth by focusing on growth potential for Enbrel and Prevenar, and streamlining the other businesses.

Ulf Wiinberg went to Nicolai High school for their education.

Some individuals on their team include Donald Kip Wolf - Head of Technical Operations & Portfolio Management, Florian Schödel - Chief Scientific Advisor, and Katalin Abraham - Chief Regulatory & Preclinical Development Officer.